By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Durata Therapeutics, Inc. 

89 Headquarters Plaza North
Suite 306
Morristown  New Jersey  07960  U.S.A.
Phone: 646-871-6480 Fax: 973-993-4865


SEARCH JOBS


Industry
Biotechnology






Company News
Durata Therapeutics, Inc.  (DRTX) Enters Into An Exclusive License And Supply Agreement With Angelini To Commercialize Dalbavancin In Certain European Territories, Russia And Turkey 7/30/2014 10:47:33 AM
Durata Therapeutics, Inc.  (DRTX) Announces The U.S. Launch Of Dalvance™ 7/18/2014 6:33:05 AM
Durata Therapeutics, Inc.  (DRTX) To Present At Upcoming Investor Conferences 6/17/2014 8:40:34 AM
The New England Journal of Medicine Publishes Data From Durata Therapeutics, Inc.  (DRTX)'s Discover Program 6/5/2014 9:09:16 AM
FDA Approves Durata Therapeutics, Inc.  (DRTX)'s Dalvance To Treat Skin Infections 5/23/2014 2:08:54 PM
Durata Therapeutics, Inc.  (DRTX) To Present At Upcoming Investor Conferences 5/9/2014 9:53:21 AM
Durata Therapeutics, Inc.  (DRTX) Reports First Quarter 2014 Financial Results 5/8/2014 9:31:52 AM
Durata Therapeutics, Inc.  (DRTX) To Present Six Dalbavancin Posters At The 24th Annual ECCMID Meeting 5/2/2014 9:30:47 AM
Durata Therapeutics, Inc.  (DRTX) To Announce First Quarter 2014 Financial Results On May 8, 2014 5/1/2014 9:04:24 AM
Durata Therapeutics, Inc.  (DRTX) Initiates Enrollment In A Phase 3b Study Of Dalvance™ In A 1500 Mg Single Dose 4/24/2014 8:56:09 AM
12345678
//-->